Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 14/20 | 0.81 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.68 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | IKBKB | O14920 | 1/20 | 0.64 |
| ▸ | CHUK | O15111 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MYLK | Q15746 | 1/20 | 0.64 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.64 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264823 | 0.92 | TMPRSS4 (0.72) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL330413 | 0.90 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL30100391 | 0.88 | TMPRSS4 (0.79) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL18341401 | 0.88 | TMPRSS4 (0.79) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL18341193 | 0.87 | TMPRSS4 (0.85) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL330166 | 0.87 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL14886093 | 0.86 | TMPRSS4 (0.76) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL18341191 | 0.86 | TMPRSS4 (0.75) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL330023 | 0.86 | TMPRSS4 (0.83) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL329995 | 0.84 | TMPRSS4 (0.73) | TMPRSS4P2RX1P2RX4P2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20060089395-A1 | Nf-kb activation inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | TMPRSS4 2764/4885P2RX1 4560/4885P2RX4 4767/4885 |
| US-20060089395-A1 | Nf-kb activation inhibitors | NFKBIA, IKBKB, NFRKB | TMPRSS4 4204/4885P2RX1 4732/4885P2RX4 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.